Overview
Employees
11-50
Mentions in press and media 8
| Date | Title | Description |
| Sign up to see | Sign up to see | Sign up to see |
| Mar 29, 2011 | North Carolina vaccine developer Chimerix names Trost new CFO | Promoted This Patient Experience Checklist Is Your Key To Success in 2021 As healthcare systems strive to recover from losses due to the pandemic, patient acquisition and retention have never been more urgent, and patient experience has nev... |
| Feb 16, 2011 | Antiviral pharma Chimerix gets $81M contract for smallpox countermeasure | Promoted Telemedicine’s potential to provide healthcare to the world’s most vulnerable Teladoc Health Head of R&D Yulun Wang highlights the impact of virtual care in underserved populations around the globe through the World Telehealth ... |
| Feb 14, 2011 | Antiviral pharma Chimerix raises $45M in series F venture round | Promoted Covid-19’s terrible toll on diabetes patients. What can be done? The public health crisis has undermined the economy and made people with chronic conditions more vulnerable and stressed. Learn more with a new report from Omada Heal... |
| North Carolina vaccine developer Chimerix names Trost new CFO | Vaccine developer Chimerix has added life sciences industry veteran Timothy Trost to its management team. Durham, North Carolina-based Chimerix has named Trost to the newly created position of senior vice president, chief financial officer.... | |
| Antiviral pharma Chimerix gets $81M contract for smallpox countermeasure | Antiviral therapeutics company Chimerix has received a federal contract that could reach $81 million in value if the company successfully develops a medical countermeasure to a smallpox bioterrorism agent. The contract awarded by the Biomed... | |
| Antiviral pharma Chimerix raises $45M in series F venture round | Antiviral therapeutics company Chimerix has raised $45 million in a sixth round of financing to support two compounds in clinical trials, one of which has potential as a weapon against biological warfare. The series F round was led by New L... | |
| RTP venture capital climate improved in Q1 but biotechs still clamor for cash | Early stage life science companies still developing their technologies can fall into a gap: too expensive to be supported by more grants or angel investments yet not far enough along to secure venture capital interest. In the worst economy ... |